Mineralys Therapeutics Acquires Lorundrostat Intellectual Property From Tanabe Pharma

Bitget2026/10/29 20:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mineralys Therapeutics acquired lorundrostat patents and know-how from Tanabe Pharma on October 27, 2026, terminating their license agreement.
Remaining obligations include commercial milestones of up to $255 million and up to $10 million for a potential second indication.
Qualifying changes of control or exclusive licensing deals including U.S. rights would accelerate $100 million of those milestone payments.
Tanabe retains first-negotiation rights for lorundrostat licenses in Japan while milestones remain unachieved and corresponding payments remain unpaid.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001933414-26-000136), on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mineralys Therapeutics Acquires Lorundrostat Intellectual Property From Tanabe Pharma

You may also like

Crypto prices